ag-538 and Neoplasms

ag-538 has been researched along with Neoplasms* in 2 studies

Reviews

2 review(s) available for ag-538 and Neoplasms

ArticleYear
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
    Bioorganic & medicinal chemistry, 2017, 05-01, Volume: 25, Issue:9

    Human apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1) is a multifunctional protein which is essential in the base excision repair (BER) pathway of DNA lesions caused by oxidation and alkylation. This protein hydrolyzes DNA adjacent to the 5'-end of an apurinic/apyrimidinic (AP) site to produce a nick with a 3'-hydroxyl group and a 5'-deoxyribose phosphate moiety or activates the DNA-binding activity of certain transcription factors through its redox function. Studies have indicated a role for APE1/Ref-1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs. Thus, this protein has potential as a target in cancer treatment. As a result, major efforts have been directed to identify small molecule inhibitors against APE1/Ref-1 activities. These agents have the potential to become anticancer drugs. The aim of this review is to present recent progress in studies of all published small molecule APE1/Ref-1 inhibitors. The structures and activities of APE1/Ref-1 inhibitors, that target both DNA repair and redox activities, are presented and discussed. To date, there is an urgent need for further development of the design and synthesis of APE1/Ref-1 inhibitors due to high importance of this protein target.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Enzyme Inhibitors; Humans; Neoplasms; Oxidation-Reduction

2017
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.
    Journal of medicinal chemistry, 2009, Aug-27, Volume: 52, Issue:16

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Neoplasms; Receptor, IGF Type 1; Signal Transduction

2009